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EDITORIAL REVIEW
Glomerulopathies of neoplasia
Proteinuria, often of sufficient magnitude to cause
the nephrotic syndrome, is a recognized systemic
manifestation of neoplastic diseases. The medical lit-
erature contains numerous examples of an apparent
temporal relationship between the development of
the nephiotic syndrome and the clinical appearance
of a tumor. Many types of tumor have been reported,
including various carcinomas, Hodgkin's disease,
other malignant lymphomas, chronic lymphocytic
leukemia, and embryonal neoplasms. The glomerular
lesions accompanying these tumors have been vari-
able and range from membranous glomerulopathy to
minimal change (lipoid) glomerulopathy and amy-
bid disease. As we shall describe, the glomerulo-
pathies of neoplastic diseases, which are associated
with the nephrotic syndrome, can be generally classi-
fied as 1) those occurring in association with carci-
nomas, 2) those occurring in association with Hodg-
kin's disease and other lymphoproliferative disorders,
and 3) lesions occurring with miscellaneous benign
and malignant neoplasms. Other glomerulopathies
have been reported, particularly in patients with
dysproteinemias. This subject has been extensively
reviewed and will not be addressed in this paper
[1—7].
Carcinomas and immune complex glomerulopathy
Although occasional instances of carcinoma and
nephrotic syndrome had been previously reported,a
Lee and associates were the first to emphasize the
apparently high prevalence of carcinoma in the adult
nephrotic population [1, 3, 8—16]. Their retrospective
study revealed that 11% of the nephrotic patients that
they had seen over a ten-year period developed a
carcinoma. Eight of the 11 patients in the latter re-
port had glomerular histological abnormalities com-
patible with membranous glomerulopathy. This
striking relationship between apparent immune com-
plex membranous glomerulopathy and carcinoma
has been a consistent feature of the subsequent liter-
ature on this subject [17—33]. Approximately 70% of
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Voihard apparently reported an instance of gastrointestinal carci-
noma and the nephrotic syndrome in 1931 [8].
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cases we have compiled from reports in the literature
and from our experience have had that histopatho-
logic diagnosis (Table 1). Immunopathologic studies
in the patients with membranous glomerulopathy
have revealed the expected granular deposition of
immunoglobulins and complement along the gb-
merular capillary loops in a manner which is compat-
ible with immune deposits. This pattern was found in
the 17 kidney specimens so analyzed (Table 2). Elec-
tron microscopy of 19 kidney specimens was also
compatible with immune complex deposition (Table
3), extensive immune aggregates being present along
the subepithelial side of the glomerular basement
membrane.
Other morphologic lesions in which the pathoge-
netic events are less well characterized have been
associated with carcinomas (Table 1). Recently sev-
eral instances of extracapillary glomerubonephritis
with nephrotic syndrome have been related to malig-
nancy [32, 33]. Immunopathologic studies supporting
an immune complex mechanism were present in two
patients in this group.
As the immunopathologic features of the glomeru-
lar lesions associated with carcinoma are analogous
to those associated with experimental chronic im-
mune complex disease, the consideration of possible
antigen-antibody systems which might be operative
in the patient with neoplasia include: 1) tumor-asso-
ciated antigens, 2) re-expressed fetal antigens, 3) viral
antigens, and 4) autologous non-tumor antigens, and
their respective antibodies. A tumor-associated an-
tigen may be defined as an antigen which is present in
the tumor, but absent from normal adult and fetal
tissue. Several instances of this type of antigen-an-
tibody system have been implicated in immune de-
posits in tumor patients [18, 25, 28]. Parenthetically,
it is perhaps not surprising that an immune complex-
mediated disease process may be manifest in tumor
patients. Host immune mechanisms directed against
tumor-associated antigens have been described
[34—37]. The nature of the humoral immune response
to tumor-associated antigens has been explored in
animal tumor models and several human tumors, and
both complement-dependent and lymphocyte-depen-
dent cytotoxic anti-tumor antibodies have been dem-
onstrated [35, 38—41]. Rossen et al have measured the
level of circulating soluble immune complexes in 136
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Table 1. RenaI morphologic findings in patients with neoplasia and nephrotic syndromes
Membrano-
No. with proliferative
Neoplastic No. of renal Minimal Membranous glomerulo-
lesion patients pathology changeb glomerulopathy nephritis' Amyloidosise Other3
Carcinoma 67 48 3 33 4 2 6
Hodgkin's disease 52 26 4 0 18 4
Malignant lymphoma
(non-Hodgkin's) 7 6 2 2 I 0 I
Leukemia 9" 9 1 4 1 1 2
Benign solid tumors 6 3 0 2 1 0 0
Embryonal tumors 12 9 1 1 0 0 7
Waldenstriim's macro-
globulinemia and
multiple myeloma 7' 7 0 0 1 6 0
Totals 171 134 33 46 8 27 20
3To be acceptable as nephrotic syndrome, patients must have had heavy proteinuria (usually more than 3.5 g per 24 hr in adults) with
hypoalbuminemia and edema, or have been stated to have nephrotic syndrome when above the data were not described.
"Minimal change glomerular lesion: glomeruli appeared normal or only slightly modified by light microscopy.
'Membranous glomerulopathy: glomeruli showed diffuse homogenous thickening of capillary walls without significant hypercellularity.
dMembranoproliferative glomerulonephritis: glomeruli showed an accentuation of lobular pattern with mesangial cell proliferation and
increased mesangial matrix, and thickening of capillary walls.
eAmyloidosis: glomeruli showed tinctorial staining of amyloid.
Other: this group includes extracapillary glomerulonephritis (5), proliferative sclerosing glomerulonephritis (4), proliferative glomerulo-
nephritis (4), unclassified glomerulonephritis (4), renal dysplasia (2), and thrombotic microangiopathy (1).
Hodgkin's disease: case reports without renal pathology are cited in references [24, 72, 85, 86, 88. 119—122].
hLeukemia: one patient had both a hypernephroma and monocytic leukemia and is included in the carcinoma group.
'Waldenström's macroglobulinemia and multiple myeloma: case reports are cited in references [123—1281.
patients with various forms of neoplasia using the
Clq binding assay. They found 82% of their patients
to have measurable levels of soluble complexes [42].
Presumably, many of these immune complexes repre-
sented tumor antigen-antibody systems in this popu-
lation. Other studies in animal systems and in man
have supported the concept that circulating tumor-
associated antigen-antibody complexes are often as-
sociated with neoplasia [43—47].
Given the above interactions between tumor-asso-
ciated antigens and the host's immune response, it
would seem plausible that some patients harboring
neoplasms would be susceptible to the glomerular
deposition of tumor-associated antigen-antibody
complexes with the subsequent induction of signifi-
cant glomerular injury. Rigorous criteria must be met
in order to establish the existence of this fascinating
phenomenon. The most conclusive immunopatholog-
ical evidence should include the unequivocal identi-
fication of both tumor-associated antigen and specific
anti-tumor antibody in the glomerular immune de-
posits. In addition, the deposits should ideally be
distributed within the glomerulus in a manner analo-
gous to that occurring in established experimental
systems of immune complex nephritis. Although
complete information in any single case is not avail-
able, individual investigations have provided suppor-
tive evidence showing either tumor-associated anti-
gens or antibodies to these antigens in glomerular
deposits in several instances of tumor-related mem-
branous glomerulopathy (Table 4). The first of these
was reported by Lewis, Loughridge, and Phillips in
Table 2. Renal immunofluorescent findings in glomeruli in patients with neoplasia and nephrotic syndrome
Neoplastic lesion
No
no.
. positive/
examined lgG IgA 1gM C3
Carcinoma l9/20a 19/20 3/9 3/10 18/18
l-lodgkin'sdisease 4/15 3/12 1/8 3/9 3/11
Malignant lymphoma
(non-Hodgkin's) 1/3 1/3 0/3 1/3 1/3
Leukemia 3/3 3/3 1/3 0/2 3/3
Benign solid tumors ND3 ND ND ND ND
Embryonal tumors I/I I/I ND ND I/I
aseventeen patients with carcinoma in whom immunofluorescent findings are reported had a histological diagnosis of membranous
glomerulopathy. Three patients had extracapillary gtomerulonephritis.
"ND = No data.
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Table 3. Renal electron microscopic findings of glomerular electron dense deposits in patients with neoplasia and nephrotic syndrome
Neoplastic lesion Total no. examined
Glomerular electron dense deposits
Subepithelial Subendothelial Mesangial Negative
Carcinoma 21 l9 l 1b ic
Hodgkin's disease 19 3 2 0 14
Malignant lymphoma
(non-Hodgkin's) 4 1 1 0 2
Leukemia 2 2 0 0 0
Benign solid tumors 2 2 0 0 0
Embryonal tumors 1 0 1d 0 0
These nineteen patients had a histological diagnosis of membranous glomerulopathy.
bsubendothelial and mesangial deposits were found in the kidney specimen of a patient with a histological diagnosis of membranoprolifera-
tive glomerulonephritis.
cThis patient had a histological diagnosis of lipoid nephrosis.
dFocal subendothelial and intramembranous deposits were found in one kidney specimen.
1971 [18]. They studied a patient who had persistent
nephrotic syndrome for three years due to mem-
branous glomerulopathy associated with an unresect-
able squamous cell bronchogenic carcinoma. These
investigators succeeded in eluting immunoglobulin
from the glomeruli and found specific reactivity
against a preparation of antigens from the patient's
tumor but not from his normal lung tissue. In addi-
tion, this antibody was shown to bind to the patient's
tumor cell membranes. Immunoglobulin with identi-
cal antigenic specificity was detected in the patient's
serum. Although these observations did not show
definite enrichment of antibody activity in the renal
eluate over that in serum, nor demonstrate the tumor
antigen in glomerular deposits, the observations were
compatible with the concept of glomerulopathy me-
diated by tumor antigen-antibody complexes. Couser
et a! demonstrated a tumor-associated antigen in the
glomerular immune deposits of a patient with colonic
adenocarcinoma and membranous glomerulopathy
[25]. They showed that a sample of the patient's
serum, obtained one week after resection of the neo-
plasm, contained antibody reactive with an antigen in
the glomerular deposit. The serum antibody reac-
tivity was abolished by absorption with a homoge-
nate of the adenocarcinoma, but not by absorption
with a simultaneously resected colonic polyp or by
normal colonic tissue, thus providing indirect evi-
dence of a tumor-associated antigen. However, the
nature of the latter antigen was not identified. Car-
cinoembryonic antigen (CEA) was not found in the
immune deposits using antisera to CEA, even though
elevated serum levels of CEA were detected in this
patient. No attempt was made to determine the reac-
tivity of the deposited antibody against tumor-asso-
ciated antigen. Weksler et al, using unabsorbed anti-
sera to a melanoma cell line, reported identification
of a tumor antigen in the glomerular deposits of a
patient who developed nephrotic syndrome during a
tumor recurrence [28]. Detailed immunopathologic
control studies have not been reported in that case.
Costanza and colleagues have reported that they
found a tumor-expressed fetal antigen, carcino-
embryonic antigen (CEA), in immune glomerular de-
posits of a patient with colonic adenocarcinoma [20].
Hence, while no single study has identified both an-
tigen and antibody, the importance of tumor-asso-
ciated and fetal antigen immune deposits in the
development of glomerular lesions appears to be
established.
Table 4. Antigen-antibody systems described in tumor-related immune complex giomerulopathy
Report Neoplasm Glomerular lesion
Antigen-antibody
system Reagent
Lewis, 1971 118]
Costanza, 1973 [20]
Bronchogenic ca
Colon adenoca
Membranous
Membranous
Tumor Ag
CEA
Eluate and tumor
Anti-CEA Ab
Couser, 1974 [25]
Weksler, 1974 [28]
Hyman, 1973 [50]
Higgins, 1974 126]
Colon adenoca
Melanoma
Hodgkin's disease
Bronchogenic ca
Membranous
Membranous
Focal proliferative
Membranous
Tumor Ag
Tumor Ag
Herpes zoster
Nuclear
Serum and tumor
Anti-melanoma Ab
Anti-viral Ab
Eluate-ANF
Ozawa, 1975 [57] Hypernephroma Minimal lesion RTE Cryoprecipitate, eluate
and anti-RTE Ab
Richard-Mendes da
Costa, 1974 [27] Bronchogenic ca Membranous Lung Ag Eluate and lung or tumor
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An alternative to the interaction of tumor-asso-
ciated or fetal antigen-antibody systems is the possi-
bility that a viral antigen is involved (Table 4). In the
latter instance, the presence of viral antigen could be
indicative of a tumor-related virus, or of an unrelated
intercurrent viral infection. That viral antigen-an-
tibody complexes could conceivably lead to the devel-
opment of immune complex disease in patients with
neoplasia has been recently demonstrated [48, 49].
Oldstone detected circulating immune complexes and
glomerular deposits of Epstein-Barr virus antibody
and complement in two patients with African Burkitt's
lymphoma [48]. Sutherland and Mardinay reported
finding the presence of oncornovirus antigen in glom-
erular mesangial immune deposits in two patients
with acute myelomonocytic leukemia [49]. Apparently
these deposits were present in insufficient amounts
to produce clinical evidence of nephritis. Hyman and
his colleagues reported finding herpes zoster viral
antigen in glomerular immune deposits in a young
child with Hodgkin's disease, cutaneous herpes
zoster, and nephrotic syndrome [50]. Although pro-
vocative, this latter demonstration of viral antigen
has to be accepted with reservation because of the
stated cross-reactivity of the antisera used in this
study with a human plasma protein.
Interesting parallel findings have been demon-
strated in several experimental animal models. AKR
mice, which spontaneously develop leukemia from
Gross murine leukemia virus, have a high incidence
of glomerular immune complex deposition contain-
ing Gross viral antigens [5 1—53]. Paris R-III mice
with virus-induced mammary tumors have a similarly
high frequency of tumor-specific viral antigen-an-
tibody complex formation and glomerular deposition
[54].
A final possibility, that the occurrence of immune
complex glomerulopathy in patients with neoplasia is
an expression of autoimmunity directed against nor-
mal antigens, also deserves consideration (Table 4). It
has been repeatedly confirmed that patients with car-
cinoma have a high incidence of non-organ specific
auto-antibodies including antinuclear factor [55, 56].
Higgins, Randall, and Still postulated that DNA-
antiDNA complexes were responsible for the devel-
opment of membranous glomerulopathy and neph-
rotic syndrome in a patient with metastatic oat cell
lung carcinoma and circulating antinuclear anti-
bodies [26]. The patient's glomeruli showed typical
subepithelial deposits containing IgG, C3, and Feul-
gen-positive material. Renal eluate had weak anti-
nuclear activity. Conclusive evidence, however, that
this eluted antibody activity represented deposited
antibody, rather than contamination of the specimen
with serum, would require demonstration of specific
antibody enrichment of eluate relative to serum,
which was not reported.
Ozawa et al have suggested that patients with renal
cell carcinoma may evoke an autoimmune response
to a normal tissue-specific antigen, renal tubular epi-
thelial antigen (RTE) [57]. This is an antigen that is
present at the brush border of the proximal tubules in
several species, including man. Renal tubular epithe-
hal antigen is the immunizing agent responsible for
the development of experimental membranous gb-
merulopathy in the Heymann model in rats [58]. One
report has considered this antigen to be involved in
the pathogenesis of some cases of human idiopathic
membranous gbomerulopathy [59]. The authors have
stated that RTE-antibody complexes were present in
serum cryoprecipitate and in glomerular immune de-
posits in three renal cell carcinoma patients. How-
ever, the pathogenetic significance of these observa-
tions is unclear because the patients did not appear to
have major clinical or histological renal lesions re-
lated to the presence of immune reactants. In addi-
tion, satisfactory immunofluorescent photomicro-
graphs illustrating the phenomenon were not
published.
An additional instance of membranous glomerubo-
pathy in a patient with an epidermoid lung carci-
noma supports the evidence that the immune com-
plex disease may be mediated by tissue-specific
antigen-antibody systems [27]. In this case, renal
eluate was shown to react with the patient's normal
lung tissue and lung tumor, as well as with lung
tumor from other patients. While this pattern of cross
reaction supports the above interpretation, an alter-
native consideration is that it may represent some
form of embryonic antigen-antibody system, possibly
CEA antigen-antibody complexes. The latter antigen
does share antigenic determinants with normal lung
glycoprotein [60, 61].
The relative extent to which tumor-associated,
fetal, viral or autoimmune antigen-antibody com-
plexes are involved in the development of a given
instance of tumor-related gbomerubopathy is un-
known. These several interesting clinical and experi-
mental observations linking the pathogenesis of the
renal disease directly to the tumor provide a chal-
lenge for future investigations.
The recorded clinical course of nephrotic syn-
drome in patients with carcinoma is sketchy, but
several features are readily apparent. Numerous
types of carcinoma have been associated with the
development of the nephrotic syndrome (Table 5).
The tumor is often occult when the patient presents
with edema. The onset of the nephrotic syndrome
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Table 5. Distribution of carcinomata by location
and histological type
Location Histological type
Number of
patients
Skin Basal cell carcinoma
Melanoma
I
I
Head and neck Squamous cell carcinoma
Thyroid adenocarcinoma
2
2
Breast Adenocarcinoma 2
Lung Squamous cell carcinoma
Undifferentiated carcinoma
Adenocarcinoma
Unclassified carcinoma
Total
6
2
I
19
28
Stomach Adenocareinoma 5
Gallbladder Adenocarcinoma 1
Colon-rectum Adenocarcinoma 7
Kidney Hypernephroma 3
Adrenal Adenocarcinoma 1
Cervix and vulva Squamous cell carcinoma 3
Ovary Adenocarcinoma I
antedated, in some instances by many months, the
clinical discovery of the tumor (Table 6). In no in-
stance was immunosuppressive therapy implicated as
a factor in the development of neoplasia, although a
few patients (4/18) had been treated for the nephrotic
syndrome with corticosteroids.
That a patient with an early, occult neoplasm may
present clinically with proteinuria due to immune
complex glomerulopathy is compatible with current
knowledge regarding host response to tumor. Soluble
serum immune complex levels have been reported to
be high early in the course of the disease [42]. Hence,
antigen-shedding by the tumor cells and host an-
tibody response to this shedding may be a very early
manifestation of the presence of a tumor.
The clinical course of these patients has been grave.
Of forty-four patients in whom the course was de-
scribed, 34 (77%) died within a relatively short time
span. The median survival of this latter group of
patients (from the onset of their clinical presentation)
was 12 months, with only a few (7/34) surviving for
two or more years. The median survival after clinical
recognition of the tumor was only three months. All
of these patients had progressive carcinomatosis as a
major contributing factor to their deaths. All but two
of these patients who died had either persistent neph-
rotic syndrome without having been given any spe-
cific treatment (23/34), or nephrotic syndrome resist-
ant to various surgical and medial therapies (9/34).
Six of the patients also developed chronic renal fail-
ure.
Although the number of patients reported to be
alive at the time of report was small (10), remission
was documented in 7 following successful resection of
the tumor, sometimes performed in conjunction with
corticosteroid therapy. Cantrell described a patient
with nephrotic syndrome and adenocarcinoma of the
stomach treated by subtotal gastrectomy who had a
complete remission which was sustained during ten
years of follow-up [17].
The recorded experience would indicate that the
nephrotic syndrome which occurs in patients with
carcinoma is as relevant a clinical problem to the
nephrologist as it is to the oncologist. These patients
often present with the renal lesion and only later are
found to have a neoplasm. The high incidence pre-
viously cited in the series by Lee, Yamauchi, and
Table 6. Temporal relationship between onset of nephrotic syndrome and recognition of tumor
Nephrotic syndrome Nephrotic syndrome manifest
.
Neoplastic
lesion
manifest before tumor
Simultaneous
after tumor
>12 mos. 7-12 mos. 4-6 mos. 1-3 mos. (Total) 1-3 mos. 4-6 mos. 7-12 mos. >12 mos. (Total)
Carcinoma 3 6 1 9 (19) 16 2 2 1 2 (7)
Hodgkin's disease:
Minimal change
glomerular lesion I 1 1 (3) 12 1 I 4 5 (II)
Membranous
glomerulopathy 1 (1) 2 1 (I)
Proliferative
glomerulonephritis 1 2 (2)
Amyloidosis 1 (1) 2 1 1 13 (15)
No pathology 4 4 (4)
Malignant lymphoma
(non-Hodgkin's) 2 1 (3) 3 1 (1)
Leukemia 3 5 (5)
Benign solid tumors 1 1 (I)
Embryonal tumors 4 1 (5) 5
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Hopper (11% of adult nephrotics) and confirmed by
Row et al (11% of adult patients with membranous
glomerulopathy) would indicate that nephrologists
must be aware of this association and its mode of
presentation [16, 30].
Hodgkin's disease, lymphoproliferative disorders, and
associated glomerulopathies
Observations of the nephrotic syndrome occurring
as a consequence of Hodgkin's disease reveal four
striking features. First, the clinicopathologic features,
as we encounter them today, are quite different from
those seen a number of years ago. In the past, amy-
loidosis was the basis of the glomerular lesion. It
usually developed insidiously, after many years of
active Hodgkin's disease, and often was a late, irre-
versible and terminal complication (Table 6). There
are 13 well documented examples of the latter phe-
nomenon from 1930 until 1962 [62—73]. Only five
additional cases have been added to the literature
since 1962 [5, 74—77]. The apparent decrease in occur-
rence of amyloid disease may well be attributable to
aggressive modern therapy. A review of the literature
during the past 14 years reveals that minimal change
glomerulopathy, membranous glomerulopathy, and
proliferative glomerulonephritis now account for the
nephrotic syndrome in most patients with Hodgkin's
disease (Tables 1, 2, 3) [23, 30, 50, 74, 77—98].
A second characteristic of these patients is the early
onset of the nephrotic syndrome. Nephrotic syn-
drome and Hodgkin's disease developed either con-
currently (15/33) or within several months of each
other (6/33) in a significant proportion of patients
(Table 6). The patients, who did not show clinical
evidence of renal disease when initially evaluated and
treated for Hodgkin's disease, developed nephrotic
syndrome coincident with tumor relapse (9/33).
Third, it is now clearly substantiated that effective
therapy directed at the neoplastic process almost
uniformly causes a remission of the nephrotic syn-
drome. All 24 patients with nephrotic syndrome due
to minimal change glomerulopathy, in whom the
clinical course was described in the report, achieved a
complete remission of their initial episode of neph-
rotic syndrome. Treatment of patients with immune
complex glomerulopathies was almost as successful
(4/6).
The fourth remarkable feature is the report of eight
relapses of the nephrotic syndrome in four patients
coinciding with periods of reactivation of Hodgkin's
disease, Most of these nephrotic episodes were also
successfully treated with anti-tumor management
(7/8).
A third of the successfully reported remissions
were associated with irradiation therapy only. The
remainder were treated with chemotherapy, sometimes
in conjunction with irradiation. These results indicate
that the glomerular lesion subsides with induction of
tumor remission and that this may be unrelated to
chemotherapy (i.e., immunosuppression and corti-
costeroids).
Although the pathogenesis of nephrotic syndrome
complicating Hodgkin's disease is not understood,
there seems to be reasonably good information to
support the concept that the nephrotic syndrome oc-
curs as a paraneoplastic process rather than a coinci-
dental event, and that the two phenomena parallel
one another clinically. The pathogenesis of minimal
change glomerulopathy in Hodgkin's disease patients
is unknown. Obvious speculations have been raised
regarding the production of a humoral factor, by the
neoplastic cells or interacting lymphocytes, which
would somehow cause damage to the glomerular cap-
illary wall, or one of its elements [99]. Tumor cells
have been demonstrated to produce proteases which
may also conceivably be capable of vascular damage
[100]. These speculations are unsupported by con-
vincing data at the present time.
Few patients with nephrotic syndrome associated
with other types of lymphoid neoplasia are available
for an analysis of course and outcome. Six adults and
one child with malignant lymphoma have had neph-
rotic syndrome (Tables 1, 2, 3) [50, 83, 101—105]. In
four patients both events manifested themselves
closely in time (Table 6). Success in treatment of the
lymphoma and the nephrotic syndrome was reported
in three of these patients. In three other patients, the
onset of the nephrotic syndrome antedated the recog-
nition of malignant lymphoma by twelve to fifteen
months (Table 6). Ghosh described a 74-yr-old man
who developed generalized lymphosarcoma one year
after an episode of nephrotic syndrome due to min-
imal change glomerulopathy was successfully treated
with corticosteroids [83]. Rabkin described a patient
with membranous glomerulopathy with nephrotic
syndrome and rapidly developing end stage kidney
disease who received immunosuppressive therapy
(azathioprine) for four months, and ten months later
developed a retroperitoneal lymphosarcoma [104].
Both of these patients died soon after recognition of
lymphoma. Nine adult patients with nephrotic syn-
drome and chronic lymphocytic leukemia have been
reported (Tables 1, 2, 3) [30, 81, 106—109]. Two
patients achieved complete renal responses and one
a partial renal response with immunosuppressive
drugs. Three died of chronic renal failure with per-
sistent leukemia.
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Glomerular lesions associated with miscellaneous benign and
malignant tumors
An appraisal of the possible relationship between
benign solid neoplasms and nephrotic syndrome is
difficult (Tables 1, 3) [16, 24, 103, 110.]. Lumeng and
Moran reported one example wherein the clinical
course suggests a relationship [110]. They described a
15-yr-old girl who presented with an enlarging caro-
tid body tumor, and 4+ proteinuria with hypoalbumin-
emia due to membranous glomerulopathy. Surgical
resection of the mass was followed three weeks later
by a complete clinical renal response, which was sus-
tained through eighteen months of follow-up. Cosby
et a!, in abstract form, reported successful treatment
of the nephrotic syndrome in three patients with sur-
gical resection of an associated benign solid tumor
[24]. Significant glomerular disease in early child-
hood (0 to 6 yr of ages) has been observed with
embryonal neoplasms. Thirteen such cases have been
associated with Wilm's tumors (nephroblastoma),
and a single instance with gonadoblastoma (Tables 1,
2, 3) [24, 30, 111—118]. The pathogenesis of the renal
disease in these cases requires further clarification.
Renal pathological analyses have indicated the prob-
ability of immune complex-mediated glomerulopathy
in one patient but the remainder are not known [118].
Summary. The glomerulopathies occurring in neo-
plastic diseases may represent, particularly in patients
with carcinoma, a manifestation of host response to
the presence of tumor antigens which may be recog-
nized as "foreign" by the immune system. Evidence
has been reviewed which supports the concept that
immune deposits in the glomerulus represent aggre-
gates of tumor-associated antigen-antibody com-
plexes. These immunopathologic findings are com-
patible with existing data demonstrating that soluble
circulating immune complexes are frequently present
early in the course of a malignancy. Our review of the
existing literature would suggest that proteinuria is
an early clinical manifestation of this immune phe-
nomenon in occult carcinoma. The prognosis of
patients with nephrotic syndrome due to neoplasia
appears to be grave. While the number of patients
with a given histologic diagnosis is too small for
statistical analysis, a median survival of three months
after first clinical manifestation of tumor in 34
patients is impressively short. Perhaps the host re-
sponse to tumor is responsible for this poor progno-
sis. Immune complexes have been detected bound to
the surface of tumor cells, where they may interfere
with lymphocyte-mediated hypersensitivity reactions
against the tumor. In addition, circulating immune
complexes may serve as "blocking factors," having
the capacity to modulate the immune response by
interaction with sensitized lymphocytes, suppressing
the cytotoxic potential of these cells. Paradoxically,
the host immune response to the "foreign" tumor
cells may explain the poor prognosis seen in patients
who develop immune complex glomerulopathy.
The glomerulopathy of Hodgkin's disease and
some other lymphoproliferative disorders is usually
minimal change glomerulopathy, a pathologic entity
of unknown pathogenesis. It has been postulated that
the glomerular damage may be the result of a hu-
moral principle derived from neoplastic cells or inter-
acting lymphocytes. Certainly tumor cells can pro-
duce proteases which could conceivably be damaging
to some element in the glomerular capillary wall.
Despite these speculations, the cause of the lesion
remains obscure. It appears that the activity of the
glomerular lesion in these Hodgkin's disease patients
correlates closely with the activity of the tumor. The
nephrotic syndrome often appears at the time of the
diagnosis of the tumor. Regression is observed with
effective anti-tumor therapy, even when this therapy
is confined to local irradiation. In some cases, sub-
sequent exacerbations and remissions of the tumor
have been associated with parallel changes in protein-
uria. In contrast to the experience with carcinomas,
there has been no indication that Hodgkin's disease
patients who develop glomerulopathy have a poorer
prognosis than other patients with this neoplasm.
Acknowledgments
Ms. Helen Ivan and Mrs. Eileen Mieszala provided
assistance in the preparation of this manuscript.
JEREMIAH W. EAGEN
EDMUND J. LEWIS
Chicago, Illinois
Reprint requests to Dr. Edmund J. Lewis, Section of Nephrology,
Rush-Presbyterian-St. Lukes Medical Center, Chicago, Illinois
60612, U.S.A.
References
I. ASK-VPMARK E.: On amyloidosis induced by tumors of the
kidney. Acta Med Scand 104:512—525, 1940
2. BERGBR L, SINKOFF MW: Systemic manifestations of hyper-
nephroma: A review of 273 cases. Am J Med 22:791—796,
1957
3. KIMBALL KG: Amyloidosis in association with neoplastic
disease: Report of an unusual case and clinicopathological
experience at Memorial Center for Cancer and Allied Dis-
eases during eleven years (1948—1958). Ann Intern Med
55:958—974, 1961
304 Eagen and Lewis
4. LE C0ULANT P, TEXIER L, MALEVILLE J, FAURETY Y:Maladie
amylolde et cancer. Pathol Biol 9:1587—1591, 1961
5. AZZOPARDI JG, LEHNER T: Systemic amyloidosis and malig-
nant disease. J. Clin Pathol 19:539—548, 1966
6. PENMAN HG, THOMSON KJ: Amyloidosis and renal adeno-
carcinoma: A postmortem study. J Pathol 107:45—47, 1972
7. MOREL-MAROGER L, VERROUST P: Glomerular lesions in
dysproteinemias. Kidney mt 5:249—252, 1974
8. VOLHARD F, cited by REVOL L, VIALA i-i, REVILLARD JP,
MANUEL Y: Protéinurie associée a des manifestations para-
neoplastiques au cours d'un cancer bronchogenic. Lyon Med
212:907—916, 1964
9. WACKER T, ALPHONSE P.: Hypoprotéinémie carcinomateuse.
He! MedActa 12:679—683, 1945
10. DE SWIET J, WELLS AL: Nephrotic syndrome associated with
renal venous thrombosis and bronchial carcinoma. Br MedJ
1:1341—1343, 1957
11. JOHNSON JR, READER R: Prognosis in the nephrotic syn-
drome: A study with particular reference to the adult and
older child. Aust Ann Med 8:200—209, 1959
12.. NESSON FIR, SPROUL LE JR, RELMAN AS, SCHWARTZ WD:
Adrenal steroids in the treatment of idiopathic nephrotic
syndrome in adults. Ann Intern Med 58:268—277, 1963
13. NicHoLs 0, ROTH SI, CASTLEMAN B, KIBBEE BU: Case rec-
ords of the Massachusetts General Hospital: Weekly clini-
copathological exercises. Case 29-1963. N Engi J Med 268:
943—953, 1963
14. REVOL L, VIALA i-i, REVILLARD JP, MANUEL Y: Protéinurie
associée a des manifestations paraneóplastiques au cours
d'un cancer bronchogenic. Lyon Med 212:907—916, 1964
IS. DOMANT A, HAZARD J, MODAl J, GUBLER J, KLEINKNECHT
D: Syndrome nphrotique apparement primitif associé a un
cortico surrénalone maIm. Bull Soc Med Hop Paris
116:1 161—I 173, 1965
16. LEE JC, YAMAUCHI H, HOPPER J JR: The association of
cancer and the nephrotic syndrome. Ann Intern Med
64:41—51, 1966
17. CANTRELL EG: Nephrotic syndrome cured by removal of
gastric carcinoma. Br Med J 2:739—740, 1969
18. LEWIS MG, LOUGHRIDGE LW, PHILLIPS TM: Immunological
studies in nephrotic syndrome associated with extrarenal ma-
lignant disease. Lancet 2:134—135, 1971
9. LOUGHRIDGE LW, LEWIS MG: Nephrotic syndrome in malig-
nant disease of non-renal origin. Lance! 1:256—258, 1971
20. C0sTANZA ME, PINN V, SCHWARTZ RS, NATHANSON L: Car-
cinoembryonic antigen-antibody complexes in a patient with
colonic carcinoma and nephrotic syndrome. N Engi J Med
289:520—522, 1973
21. GERMUTH FC JR., RODRIQUEZ E: Immunopathology of the
Renal Glomerulus: Immune Complex Deposit and Antibase-
ment Membrane Disease, Boston, Little, Brown & Co., 1973,
p. 90
22. RICHARD C, DUPONT E, DUPUIS F, POTVLIEGE P, TOUSSAINT
C: Syndrome nephrotique associé au cancer bronchique. J
Urol Néphrol 79:745—748, 1973
23. ASAMER H, STUHLINGER W, DITTRICH P: Das para-
neoplastische nephrotische syndrom. Deuische Med Woch
99:573—575, 1974
24. COSBY R, YAMAUCHI H, LEE JC, HOPPER J JR: Tumor related
renal lesions—reversal following tumor excision. C/in Res
22:l36A, 1974
25. COUSER WG, WAGONFELD JB, SPARGO BH, LEWIS EJ: Gb-
merular deposition of tumor antigen in membranous nephro-
pathy associated with colonic carcinoma. Am J Med
57:962—970, 1974
26. HIGGINs MR, RANDALL RE, STILL WJS: Nephrotic syn-
drome with oat-cell carcinoma. Br MedJ 3:450—451, 1974
27. RICHARD-MENDES DA COSTA C, DUPONT E, HAMERS H,
HOOGHE R, DUPUIS E, POTVLIEGE R: Nephrotic syndrome in
bronchogenic carcinoma: Report of two cases with immu-
nochemical studies. Clin Nephrol 2:245—251, 1974
28. WEKSLER ME, CAREY T, DAY N, SUSIN M, SHERMAN R,
BECKER C: Nephrotic syndrome in malignant melanoma:
Demonstration of melanoma antigen-antibody in kidney.
Kidney mt 6:1 l2A, 1974
29. HEATON JM, MENZIN MA, CARNEY DN: Extrarenal malig-
nancy and the nephrotic syndrome. J Cliii Pathol 28:944—946,
1975
30. Row PG, CAMERON JS, TURNER DR, EVANS DG, WHITE
RHR, OGG CS, CHANTLER C, BROWN CB: Membranous
nephropathy: Long-term follow-up and association with neo-
plasia. Quart J Med 44:207—239, 1975
31. GI.ASSOCK RJ, BENNETT CM: The glomerulopathies, Chapter
23, in The Kidney, edited by BRENNER BM, RECTOR F, Phila-
delphia, W.B. Saunders Company, 1976, Vol. 2, pp.
1013—1014
32. HOPPER J JR, BIAVA CB, NAUGHTON JL: Glomerular extra-
capillary proliferation (crescentic glomerulonephritis) asso-
ciated with non-renal malignancies (abstr.). Kidney bit 10:544,
1976
33. WIIITWORTH JA, MOREL-MAROGER L, MIGNON F, RICHET
0: The significance of extracapillary glomerulonephritis.
Nephron 16:1—19, 1976
34. SMITH RT: Tumor-specific immune mechanisms. N Engl J
Med 278:1207—1214, 1968
35. BALDWIN RW: Tumor-specific antigens, in The Phys-
iopathology of Cancer, Biology and Biochemistry, edited by
HOMBURGER F, SHUBIK P, Basel S. Karger, 1974, Vol. 1,
pp. 334—392
36. BALDWIN RW, EMBLETON MJ, PRICE MR, ROBINS A: Im-
munity in the tumor-bearing host and its modification by
serum factors. Cancer 34:1452—1460, 1974
37. MAVLIGIT CM, GUTTERMAN JV, MCBRIDE CM, HERSH EM:
Cell-mediated immunity to human solid tumors: In vitro
detection by lymphocyte blastogenic responses to cell-asso-
ciated and solubilized tumor antigens, in Recent Results in
Cancer Research. Investigation and Stimulation of Immunity
in Cancer Patients, edited by MATNE 0, WEINER R, New
York, Springer-Verlag, 1974, pp. 84—96
38. POLLACK 5, HEPPNER G, BRAWN Ri, NELSON K: Specific
killing of tumor cells in vitro in the presence of normal
lymphoid cells and sera from hosts immune to tumor anti-
gens. Int J Cancer 9:316—323, 1972
39. HELLSTROM 1, HELLSTROM KE, WARNER GA: Increase of
lymphocyte-mediated tumor-cell destruction by certain
patient Sera. mt J Cancer 12:348—353, 1973
40. HAKALA TR, LANGE PH: Serum induced lymphoid cell me-
diated cytotoxicity to human transitional cell carcinomas of
the genitourinary tract. Science 184:795—797, 1974
41. ORTIZ DE LANDAZURI M, KEDAR E, FAHEY JL: Antibody-
dependent cellular cytotoxicity to a syngeneic Gross virus-
induced lymphoma. J Nat! Cancer Inst 52:147—152, 1974
42. R0SSEN RD REISBERG MA, HERSH EM, GUTTERMAN JU:
Measurement of soluble immune complexes: A guide to
prognosis in cancer patients. Clin Res 24:462A, 1976
43. HELLSTROM I, HELLSTROM KE, SJOGREN HO, WARNER GA:
Serum factors in tumor-free patients cancelling the blocking
of cell-mediated tumor immunity. mt i Cancer 8:185—191,
1971
44. SJOGREN, HO, HELLSTROM I, BANSAL SC, HELLSTROM KE:
Glomerulopathies of neoplasia 305
Suggestive evidence that "blocking antibodies" of tumor
bearing individuals may be antigen-antibody complexes.
Proc NatlAcadSci USA 68:1372—1375, 1971
45. HELLSTROM I, HELLSTROM KE: Cell-mediated immune reac-
tions to tumor antigens with particular emphasis on immun-
ity to human neoplasms. Cancer 34:1461—1468, 1974
46. JOSE DG, SESHADRI R: Circulating immune complexes in
human neuroblastoma: Direct assay and role in blocking
specific cellular immunity. hit J Cancer 13:824—838, 1974
47. BALDWIN RW, PRICE MR: Tumor antigens and tumor-host
relationships, in Annual Review of Medicine, edited by CRE-
GER WB, C0GGINs CH, HANCOCK EW, Palo Alto, Califor-
nia, Annual Reviews, Inc., 1976, Vol. 27, pp. 15 1—163
48. OLDSTONE MBA, THEorILopouLos AN, GUNVN P, KLEIN
G: Immune complexes associated with neoplasia: Presence of
Epstein-Barr virus antigen-antibody complexes in Burkitt's
lymphoma. Intervirology 4:292—302, 1974
49. SUTHERLAND JC, MARDINAY MR: Immune complex disease
in the kidneys of lymphoma-leukemia patients: The presence
of an oncornovirus-related antigen. J Nail Cancer Inst
50:633—644, 1973
50. HYMAN LR, BURKHOLDER PM, Joo PA, SEGAR WE: Malig-
nant lymphoma and nephrotic syndrome: A clini-
copathologic analysis with light, immunofluorescence, and
electron microscopy of the renal lesions. J Pediatr
82:207—217, 1973
SI. OLDSTONE MBA, A0KI T, DIXON FJ: The antibody response
of mice to murine leukemia virus in spontaneous infection:
Absence of classical immunologic tolerance. Proc Nail Acad
Sci USA 69:134—138, 1972
52. OLDSTONE MBA, TISI-ION A, T0NIETTI, G, DixoN FJ: Im-
mune complex disease associated with spontaneous murine
leukemia: Incidence and pathogenesis of glomerulonephritis.
C/in Inimunol Immunopaihol 1:6—14, 1972
53. PASCAL RR, Koss MN, KASSAL RL: Glomerulonephritis
associated with immune complex deposits and viral particles
in spontaneous murine leukemia. An electron microscopic
study with immunofluorescence. Lab Invest 29:159—165, 1973
54. PASCAL RR, ROLLWAGEN FM, HARDING TA, SCIAVINE WA:
Glomerular immune complex deposits associated with mouse
mammary tumor. Cancer Res 35:302—304, 1975
55. WHITEHOUSE JMA, HosBoRow EJ: Smooth muscle antibody
in malignant disease. Br Med J 4:511—513, 1971
56. FRIOU GJ: Current knowledge and concepts of the relation-
ship of malignancy, autoimmunity and immunologic disease.
Ann NY AcadSci 230:23—54, 1974
57. OZAWA T, Pi.uss R, LACHERJ, BOEDECKER E, GUGGENHEIM
S, HAMMON DW, MCINTOSH R: Endogenous immune com-
plex nephropathy associated with malignancy: I. Studies on
the nature and immunopathogenic significance of glomerular
bound antigen and antibody, isolation and characterization
of tumor specific antigen and antibody and circulating im-
mune complexes. Quart J Med 44:523—541, 1975
58. EDGINGTON TS, GLASSOCK Ri, DIXON iF: Autologous im-
mune complex nephritis induced with renal tubular antigen:
I. Identification and isolation of the pathogenetic antigen. J
Exp Med 127:555—572, 1968
59. NARUSE T, MIYAKAWA Y, KITAMURA K: Membranous
glomerulonephritis mediated by renal tubular epithelial an-
tigen-antibody complex. J Allergy C/in Immunol 54:311—318,
1974
60. SIZARET P, MARTIN F: Carcinoembryonic antigen in extracts
of pulmonary cancers. J Nail Cancer Inst 50:807—8 10, 1973
61. MACH J-P, SINGH K, PERRINJAQUET J, CARRELS, MERENDA
C, MACDONALD D, HOLBURN A: Relationship between car-
cinoembryonic antigen and blood group antigens A, B and
Lewis. Ann NY Acad Sci 259:389—403, 1975
62. BANNICK EG, BARKER NW: Diffuse amyloidosis of unknown
etiology. Med Clinics N Am 14:773—781, 1930
63. TOB1AS JW, COLOMBI FA: Amiloidosis generalizada por lin-
fogranulomatosis abdominal. Rev Med Y Cien A Fines
2:927—935, 1940
64. LEHMAN RG: Hodgkin's disease complicated by amyloidosis
and a nephrotic syndrome: Case report. Ohio State Med J
39:232—233, 1943
65. CERVERA FG, PODESTA LD: La amiloidosis generalizada en
Ia enfermedad de Hodgkin-Paltauf-Sternberg. Prensa Med
Argent 33:2082—2085, 1946
66. SHORT CL, MALLORY TB, CASTLEMAN B, PARRIS EE: Case
records of the Massachusetts General Hospital. Weekly clini-
copathological exercises. Case 35391. N EngI J Med
241:497—500, 1949
67. WALLACE SL, FELDMAN DJ, BERLIN I, HARRIS C, GLASS IA:
Amyloidosis in Hodgkin's disease. Am J Med 8:552—557,
1950
68. GLEDHILL RC, SHILLITOE Al: Purpura and amyloidosis in
Hodgkin's disease. Br Med J 1:1336—1337, 1952
69. TEILUM G: Studies on the pathogenesis of amyloidosis: II.
Effect of nitrogen mustard in inducing amyloidosis. J Lab
C/in Med 43:367—374, 1954
70. SHERMAN MJ, MORALES JB, BAYRD ED, SCHIERMAN WD:
Amyloid nephrosis secondary to Hodgkin's disease. JAMA
Arch Intern Med 95:618—621, 1955
71. LEONARD BJ: Chronic lymphatic leukemia and the nephrotic
syndrome. Lancet 1:1356—1357, 1957
72. WINAWER Si, FELDMAN SM: Amyloid nephrosis in Hodg-
kin's disease. Arch Intern Med 104:793—796, 1959
73. RICHMOND i, SHERMAN RS, DIAMOND HD, CRAVER LF:
Renal lesions associated with malignant lymphoma. Am J
Med 32:184—207, 1962
74. KIELY iM, WAGONER RD, HOLLEY KE: Renal complications
of lymphoma. Ann Intern Med 71:1159—1175, 1969
75. AACH R, KISSANE J: Clinicopathologic conference: Hodg-
kin's disease complicated by thrombocytopenia and neph-
rotic syndrome. Am J Med 5 1:109—120, 1971
76. FALKSON G, FALKSON HC: Amyloidosis in Hodgkin's dis-
ease. S AJr Mcdi 47:62—64, 1973
77. YuM MN, EDWARDS JL, KLEIT 5: Glomerular lesions in
Hodgkin's disease. Arch Paihol 99:645—649, 1975
78. FOTH R, BADER K, KARK R: Development of nephrotic
syndrome secondary to renal vein thrombosis with broncho-
genie carcinoma and Hodgkin's disease. Ill Med i
125:505—509, 1964
79. Kiy Y: Sindrome nefrôtica associada a doenca de Hodgkin.
Rev Hosp C/in Fac Med S Paulo 22:186—191, 1967
80. MILLER DG: The association of immune disease and malig-
nant lymphoma. Ann Intern Med 66:507—521, 1967
81. BR000VSKY, HS, SAMUELS ML, MIGLIORE P1, HOWE CD:
Chronic lymphocytic leukemia, Hodgkin's disease, and the
nephrotic syndrome. Arch Intern Med 121:71—75, 1968
82. HARDIN JG JR, COKER AS, BLANTON iH: Medicine Grand
Rounds from the University of Alabama Medical Center.
SAJr Mcdi 62:1111—1118, 1969
83. GHOSH (Banerji) L, MUEHRCKE RC: The nephrotic syn-
drome: A prodrome to lymphoma. Ann Intern Med
72:379—382, 1970
84. PIESSENS WF, ZEICHER M: Hodgkin's disease causing a re-
versible nephrotic syndrome by compression of the inferior
vena cava. Cancer 25:880—884, 1970
306 Eagen and Lewis
85. BICHEL J, BJIRN JENSEN K: Nephrotic syndrome and Hodg-
kin's disease. Lance! 2:1425—1426, 1971
86. JACKSON RH, 00 M: Nephrotic syndrome with Hodgkin's
disease. Lance! 2:821—822, 1971
87. LOwRY WS, MUNZENRIDER JE, LYNCH GA: Nephrotic Syn-
drome in Hodgkin's disease. Lance! 1:1127, 1971
88. PLACER J, STUTZMAN L: Acute nephrotic syndrome as a
manifestation of active Hodgkin's disease: Report of four
cases and review of the literature. Am J Med 50:56—66, 1971
89. FROOM DW, FRANKLIN WA, HANO JE, POTTER EU: Immune
deposits in Hodgkin's disease with nephrotic syndrome. Arch
Paihol 94:547—553, 1972
90. HANSEN EH, SKOv PE, ASKJAER SA, ALBERTSEN K: Hodg-
kin's disease associated with the nephrotic syndrome without
kidney lesion. Ada Med Scand 191:307—3 13, 1972
9!. PERLIN E, POWERS JM, DICKSON LG, MOQUIN RB: The
nephrotic syndrome in Hodgkin's disease. Med Ann DC
41:354—356, 1972
92. SHERMAN RL, SUSIN M, WEKSLER ME, BECKER EL: Lipoid
nephrosis in Hodgkin's disease. AmJMed52:699—706, 1972
93. CARPENTER CB, CASTLEMAN B, SCULLY RE, MCNEELY BU:
Case records of the Massachusetts General Hospital. Weekly
clinicopathological exercises. Case 49—1973. N Engl i Med
289:1241—1247, 1973
94. HAYSLETT JP, KASHGARIAN M, BENSCH KG, SPARGO BJ,
FREEDMAN LR, EPSTEIN FH: Clinicopathological correla-
tions in the nephrotic syndrome due to primary renal disease.
Medicine 52:93—120, 1973
95. L0KICH ii, GALVANEK EG, MOLONEY WC: Nephrosis of
Hodgkin's disease. Arch Intern Med 132:597—600, 1973
96. LARSON LS, FRITZ RD: Nephrotic syndrome in association
with Hodgkin's disease. Wis Mcdi 75:14—17, 1976
97. MOORTHY AV, ZIMMERMAN SW, BURKHOIOER PM: Neph-
rotic syndrome in Hodgkin's disease. Evidence for pathogen-
esis alternative to immune complex disease. Am i Med
61:471—477, 1976
98. ROUTLEDGE RC, HANN lM, MORRIS JONES PH: Hodgkin's
disease complicated by the nephrotic syndrome. Cancer
38:1735—1740, 1976
99. SHALIIOUII RJ: Pathogenesis of lipoid nephrosis a disorder of
T-cell function. Lance! 2:556—559, 1974
100. SCHAPIRA F: lsoenzymes and cancer, in Advances in Cancer
Research, edited by KLEIN G, WEINHOUSE S, HA000W A,
New York, Academic Press, 1973 Vol. 18, pp. 77—153
101. MUGGIA FM: Glomerulonephritis or nephrotic syndrome in
malignant lymphoma, reticulum-cell type. Lancet 1:805, 1971
102. SAGEL J, MULLER J, LOGAN E: Lymphoma and nephrotic
syndrome. S Air Mcdi 45:79—80, 1971
103. GLUCK MC, GAILo G, LOWENSTEIN J, BALDWIN DS: Mem-
branous glomerulonephritis: Evaluation of clinical and path-
ologic features. Ann Intern Med 78:1—12, 1973
104. RABKIN R, THATCtIER GN, DIAMOND LH, EALES L: The
nephrotic syndrome, malignancy and immunosuppresslon.
S Afr Med J 47:605—606, 1973
105. GAGLIANO RG, COSTANZI JJ, BEATHARD GA, SARLES HE,
BELL JD: The nephrotic syndrome associated with neoplasia:
an unusual paraneoplastic syndrome. Report of a case and
review of the literature. Am J Med 60:1026—1031, 1976
106. SCOTT RB: Leukemia. Lance! 1:1 162—1167, 1957
107. MANDALENAKIS N, MENDOZA N, PIRANI CL, POLLACK VE:
Lobular glomerulonephritis and membranoproliferatlve
glomerulonephritis: A clinical and pathologic study based on
renal biopsies. Medicine 50:319—355, 1971
108. CAMERON S, OGG CS: Nephrotic syndrome in chronic lym-
phocytic leukemia. Br Mcdi 4:164, 1974
109. DATHAN iRE, HEYWORTH MF, MACIVER AG: Nephrotic
syndrome in chronic lymphocytic leukemia. Br Med J
3:655—658, 1974
110. LUMEN0 J, MORAN JF: Carotid body tumor associated with
mild rnembranous glomerulopathy. Ann Intern Med
65:1 266—1270, 1966
Ill. SMITH NJ: Glomerulonephritis, Wilm's tumor, and horseshoe
kidney in an infant. Arch Paihol 42:549—554, 1946
112. FRASIER SD, BASHORE RA, MOSIER HD: Gonadoblastoma
associated with pure gonadal dysgenesis in monzygous twins.
i Pediair 64:740—745, 1964
113. ZUNIN C, SOAVE F: Association of nephrotic syndrome and
nephroblastoma in siblings. Ann Pediatr 203:29—38, 1964
114. DENYS P, MALRAUX P, VAN DER BERGHE H, TANGHE W,
PROESMANS W: Association d'un syndrome anatomo-pathol-
ogique: Dc pseudohermaphrodisme maseulin, d'une tumeur
de Wilms, d'une nephropathie parenchymateuse et d'un
mosaicisme XX/XY. Arch Fr Pediatr 24:729—739, 1967
115. LINEs DR.: Nephrotic syndrome and nephroblastoma. i
Pediair 72:264—265, 1968
116. DRASII A, SHERMAN F, HARTMANN WH, BLIZZARD RM: A
syndrome of pseudohermaphroditism, Wilm's tumor, hyper-
tension, and degenerative renal disease. J Pediatr 76:585—593,
1970
117. SPEAR GS, HYDE TP, GRUPPO RA, SLUSSER R: Pseudoher-
maphroditism, glomerulonephritis with the nephrotic syn-
drome, and Wilm's tumor in infancy. J Pediair 79:677—681,
1971
118. BARAKAT AY, PAPADOPOULOU ZL, CHANDRA RS, HOLLER-
MAN CE: Pseudohermaphroditism, nephron disorder and
Wilm's tumor: A unifying concept. Pediatrics 54:366—369,
1974
119. ROHMER P, SACREZ R: Un cas de nephrose lipoidique au
cours d'une maladie de Hodgkin. S!rasbourg Med 108:
45—55, 1948
120. PAPILLON J, PINET F, BOUVET R, PINET A, CHASSHARD JL: A
propos de deux cas de manifestations urinaires de Ia maladie
de Hodgkin (Syndrome nêphrotique, localization unétérale).
J Radiol Elecirol Med NucI 38:974—976, 1957
121. TAPIE J, LA PORTE J, RICALENS 5: Syndrome nephrotique au
cours de Ia maladie de Hodgkin-Sternberg. Presse Med
65:287—293. 1957
122. MEHTA SR, KUMAR KK,GUPTA ML: Hodgkin's disease with
nephrotic syndrome and erythema multforme. i Indian Med
Assoc 48:279—282, 1967
123. GASSNER C, BITTAR EE, PARRISH AE: Macroglobulinemia
and amyloid nephrosis. Report of a case. Med Ann DC
30:342—343, 373—374, 1961
124. FORGET BG, SQUIRE JW, SHELDON H: Waldenström's
macroglobulinemia with generalized amyloidosis, Arch Intern
Mcd 118:363—375, 1966
125. BRANDT K, CATIICART ES, COHEN AS: A clinical analysis of
the course and prognosis of 42 patients with amyloidosis. Am
i Med 44:955—969, 1968
126. LIN JH, OROFIN0 D, SHERlOCK J, LETTERI J, DUFFY JL:
Waldenström's macroglobulinemia, mesangiocapillary glom-
erulonephritis, angiitis and myositis. Nephron 10:262—270,
973
127. SCOTT RB, EI.MORE S MCD, BRACKETT NC, HARRIS WO JR.
STill. WJS: Neuropathic joint disease (Charcot joints) in
Waldenström's macroglobulinemia with amyloidosis. Am f
Med 54:535—538, 1973
128. Ooi BS, PESCE AJ, POLI.ACK yE, MANDAI.ENAKIS N: Mul-
tiple myeloma with massive proteinuria and terminal renal
failure. Am J Med 52:538—546, 1972
